MET and non-small cell lung carcinoma: Amivantamab, a bispecific monoclonal antibody directed against the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET), has demonstrated significant clinical activity and is increasingly incorporated into frontline regimens for EGFR-mutant non-small cell lung cancer (NSCLC).